Which has preferable valuation & earnings, OBIO or NYXH?

Orchestra BioMed has higher revenue and earnings than Nyxoah. Orchestra BioMed is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orchestra BioMed $33.48M 7.49 -$52.70M -$0.97 N/A Nyxoah $11.33M 5.88 -$101.92M -$2.48 N/A

Is OBIO or NYXH more profitable?

Orchestra BioMed has a net margin of -166.96% compared to Nyxoah's net margin of -543.21%. Orchestra BioMed's return on equity of -157.46% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Orchestra BioMed -166.96% -157.46% -60.18% Nyxoah -543.21% -163.73% -80.24%

Does the media refer more to OBIO or NYXH?

In the previous week, Nyxoah had 2 more articles in the media than Orchestra BioMed. MarketBeat recorded 3 mentions for Nyxoah and 1 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 0.00 equaled Nyxoah'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nyxoah 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NYXH or TMCI?

In the previous week, Nyxoah had 2 more articles in the media than Treace Medical Concepts. MarketBeat recorded 3 mentions for Nyxoah and 1 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 0.59 beat Nyxoah's score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Treace Medical Concepts 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, NYXH or PROF?

Profound Medical has higher revenue and earnings than Nyxoah. Profound Medical is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $11.33M 5.88 -$101.92M -$2.48 N/A Profound Medical $16.10M 15.37 -$42.57M -$1.24 N/A

Is NYXH or PROF more profitable?

Profound Medical has a net margin of -206.76% compared to Nyxoah's net margin of -543.21%. Profound Medical's return on equity of -78.88% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -543.21% -163.73% -80.24% Profound Medical -206.76% -78.88% -64.06%

Is NYXH or LUCD more profitable?

Nyxoah has a net margin of -543.21% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -543.21% -163.73% -80.24% Lucid Diagnostics -876.72% N/A -116.26%

Does the media prefer NYXH or LUCD?

In the previous week, Nyxoah and Nyxoah both had 3 articles in the media. Nyxoah's average media sentiment score of 0.00 equaled Lucid Diagnostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, SMTI or NYXH?

Sanara MedTech has higher revenue and earnings than Nyxoah. Sanara MedTech is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanara MedTech $107.48M 2.12 -$37.56M -$3.77 N/A Nyxoah $11.33M 5.88 -$101.92M -$2.48 N/A

Is SMTI or NYXH more profitable?

Sanara MedTech has a net margin of -31.23% compared to Nyxoah's net margin of -543.21%. Sanara MedTech's return on equity of -3.19% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -31.23% -3.19% -0.56% Nyxoah -543.21% -163.73% -80.24%

Does the media refer more to SMTI or NYXH?

In the previous week, Nyxoah had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 3 mentions for Nyxoah and 1 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.00 equaled Nyxoah'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nyxoah 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nyxoah (NYXH) Competitors

$1.72 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.72 0.00 (-0.29%)

As of 07/2/2026 06:24 PM Eastern

Compare

NYXH vs. OBIO, TMCI, PROF, LUCD, and SMTI

Should you buy Nyxoah stock or one of its competitors? MarketBeat compares Nyxoah with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nyxoah include Orchestra BioMed (OBIO), Treace Medical Concepts (TMCI), Profound Medical (PROF), Lucid Diagnostics (LUCD), and Sanara MedTech (SMTI). These companies are all part of the "medical equipment" industry.

How does Nyxoah compare to Orchestra BioMed?

Orchestra BioMed (NASDAQ:OBIO) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Orchestra BioMed has higher revenue and earnings than Nyxoah. Orchestra BioMed is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	7.49	-$52.70M	-$0.97	N/A
Nyxoah	$11.33M	5.88	-$101.92M	-$2.48	N/A

Orchestra BioMed currently has a consensus price target of $13.60, indicating a potential upside of 224.58%. Nyxoah has a consensus price target of $7.00, indicating a potential upside of 306.98%. Given Nyxoah's higher probable upside, analysts clearly believe Nyxoah is more favorable than Orchestra BioMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Orchestra BioMed has a net margin of -166.96% compared to Nyxoah's net margin of -543.21%. Orchestra BioMed's return on equity of -157.46% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
Nyxoah	-543.21%	-163.73%	-80.24%

In the previous week, Nyxoah had 2 more articles in the media than Orchestra BioMed. MarketBeat recorded 3 mentions for Nyxoah and 1 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 0.00 equaled Nyxoah'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Orchestra BioMed has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Nyxoah has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

53.2% of Orchestra BioMed shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by insiders. Comparatively, 17.1% of Nyxoah shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Orchestra BioMed beats Nyxoah on 10 of the 15 factors compared between the two stocks.

How does Nyxoah compare to Treace Medical Concepts?

Nyxoah (NASDAQ:NYXH) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

84.1% of Treace Medical Concepts shares are held by institutional investors. 17.1% of Nyxoah shares are held by company insiders. Comparatively, 23.4% of Treace Medical Concepts shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Treace Medical Concepts has a net margin of -29.44% compared to Nyxoah's net margin of -543.21%. Treace Medical Concepts' return on equity of -67.04% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
Treace Medical Concepts	-29.44%	-67.04%	-30.28%

Nyxoah has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

In the previous week, Nyxoah had 2 more articles in the media than Treace Medical Concepts. MarketBeat recorded 3 mentions for Nyxoah and 1 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 0.59 beat Nyxoah's score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Treace Medical Concepts	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Treace Medical Concepts has higher revenue and earnings than Nyxoah. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	5.88	-$101.92M	-$2.48	N/A
Treace Medical Concepts	$212.69M	1.28	-$59M	-$0.97	N/A

Nyxoah presently has a consensus price target of $7.00, suggesting a potential upside of 306.98%. Treace Medical Concepts has a consensus price target of $4.77, suggesting a potential upside of 13.30%. Given Nyxoah's stronger consensus rating and higher probable upside, research analysts plainly believe Nyxoah is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

Summary

Treace Medical Concepts beats Nyxoah on 9 of the 16 factors compared between the two stocks.

How does Nyxoah compare to Profound Medical?

Nyxoah (NASDAQ:NYXH) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Nyxoah presently has a consensus price target of $7.00, suggesting a potential upside of 306.98%. Profound Medical has a consensus price target of $12.00, suggesting a potential upside of 76.21%. Given Nyxoah's stronger consensus rating and higher probable upside, research analysts plainly believe Nyxoah is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Nyxoah had 3 more articles in the media than Profound Medical. MarketBeat recorded 3 mentions for Nyxoah and 0 mentions for Profound Medical. Nyxoah's average media sentiment score of 0.00 equaled Profound Medical'saverage media sentiment score.

Company	Overall Sentiment
Nyxoah	Neutral
Profound Medical	Neutral

Nyxoah has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

Profound Medical has higher revenue and earnings than Nyxoah. Profound Medical is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	5.88	-$101.92M	-$2.48	N/A
Profound Medical	$16.10M	15.37	-$42.57M	-$1.24	N/A

Profound Medical has a net margin of -206.76% compared to Nyxoah's net margin of -543.21%. Profound Medical's return on equity of -78.88% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
Profound Medical	-206.76%	-78.88%	-64.06%

47.9% of Profound Medical shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Profound Medical beats Nyxoah on 8 of the 15 factors compared between the two stocks.

How does Nyxoah compare to Lucid Diagnostics?

Nyxoah (NASDAQ:NYXH) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Nyxoah has a net margin of -543.21% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
Lucid Diagnostics	-876.72%	N/A	-116.26%

In the previous week, Nyxoah and Nyxoah both had 3 articles in the media. Nyxoah's average media sentiment score of 0.00 equaled Lucid Diagnostics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nyxoah currently has a consensus target price of $7.00, suggesting a potential upside of 306.98%. Lucid Diagnostics has a consensus target price of $4.19, suggesting a potential upside of 291.36%. Given Nyxoah's higher possible upside, analysts clearly believe Nyxoah is more favorable than Lucid Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Nyxoah has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Lucid Diagnostics has lower revenue, but higher earnings than Nyxoah. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	5.88	-$101.92M	-$2.48	N/A
Lucid Diagnostics	$4.71M	46.13	-$58.01M	-$0.47	N/A

74.0% of Lucid Diagnostics shares are held by institutional investors. 17.1% of Nyxoah shares are held by company insiders. Comparatively, 6.9% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Nyxoah and Lucid Diagnostics tied by winning 7 of the 14 factors compared between the two stocks.

How does Nyxoah compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

In the previous week, Nyxoah had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 3 mentions for Nyxoah and 1 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.00 equaled Nyxoah'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sanara MedTech has higher revenue and earnings than Nyxoah. Sanara MedTech is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$107.48M	2.12	-$37.56M	-$3.77	N/A
Nyxoah	$11.33M	5.88	-$101.92M	-$2.48	N/A

8.1% of Sanara MedTech shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sanara MedTech has a net margin of -31.23% compared to Nyxoah's net margin of -543.21%. Sanara MedTech's return on equity of -3.19% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
Nyxoah	-543.21%	-163.73%	-80.24%

Sanara MedTech has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Nyxoah has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

Sanara MedTech currently has a consensus price target of $34.00, suggesting a potential upside of 36.88%. Nyxoah has a consensus price target of $7.00, suggesting a potential upside of 306.98%. Given Nyxoah's higher probable upside, analysts clearly believe Nyxoah is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Sanara MedTech beats Nyxoah on 9 of the 15 factors compared between the two stocks.

Get Nyxoah News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NYXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NYXH vs. The Competition

Export

Metric	Nyxoah	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$66.67M	$1.83B	$7.16B	$12.48B
Dividend Yield	N/A	N/A	2.66%	6.52%
P/E Ratio	-0.69	81.75	28.02	24.70
Price / Sales	5.88	7.15	540.37	99.46
Price / Cash	N/A	26.08	49.26	57.09
Price / Book	1.20	5.75	10.96	6.46
Net Income	-$101.92M	-$54.76M	$3.57B	$337.01M
7 Day Performance	2.99%	2.95%	2.12%	1.69%
1 Month Performance	18.62%	2.81%	5.25%	3.81%
1 Year Performance	-77.86%	-0.07%	33.29%	23.90%

Nyxoah Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NYXH Nyxoah	2.3641 of 5 stars	$1.72 flat	$7.00 +307.0%	-77.9%	$66.67M	$11.33M	N/A	110
OBIO Orchestra BioMed	3.6128 of 5 stars	$4.32 -9.1%	$13.60 +214.8%	+44.7%	$258.69M	$32.72M	N/A	4	Gap Up
TMCI Treace Medical Concepts	2.1858 of 5 stars	$3.98 -6.8%	$4.77 +19.8%	-30.4%	$258.20M	$207.32M	N/A	250	Positive News
PROF Profound Medical	1.6145 of 5 stars	$6.65 +0.9%	$12.00 +80.5%	+13.8%	$241.65M	$18.81M	N/A	150
LUCD Lucid Diagnostics	3.4493 of 5 stars	$1.07 +1.9%	$4.19 +291.4%	-1.5%	$217.28M	$5.13M	N/A	70	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NYXH) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nyxoah (NYXH) Competitors

NYXH vs. OBIO, TMCI, PROF, LUCD, and SMTI

How does Nyxoah compare to Orchestra BioMed?

Summary

How does Nyxoah compare to Treace Medical Concepts?

Summary

How does Nyxoah compare to Profound Medical?

Summary

How does Nyxoah compare to Lucid Diagnostics?

Summary

How does Nyxoah compare to Sanara MedTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NYXH vs. The Competition

Nyxoah Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nyxoah (NYXH) Competitors

NYXH vs. OBIO, TMCI, PROF, LUCD, and SMTI

How does Nyxoah compare to Orchestra BioMed?

Which has preferable valuation & earnings, OBIO or NYXH?

Do analysts recommend OBIO or NYXH?

Is OBIO or NYXH more profitable?

Does the media refer more to OBIO or NYXH?

Which has more volatility and risk, OBIO or NYXH?

Do insiders and institutionals have more ownership in OBIO or NYXH?

Summary

How does Nyxoah compare to Treace Medical Concepts?

Do institutionals and insiders hold more shares of NYXH or TMCI?

Is NYXH or TMCI more profitable?

Which has more risk & volatility, NYXH or TMCI?

Does the media prefer NYXH or TMCI?

Which has higher valuation & earnings, NYXH or TMCI?

Do analysts rate NYXH or TMCI?

Summary

How does Nyxoah compare to Profound Medical?

Do analysts prefer NYXH or PROF?

Does the media prefer NYXH or PROF?

Which has more volatility and risk, NYXH or PROF?

Which has preferable earnings & valuation, NYXH or PROF?

Is NYXH or PROF more profitable?

Do institutionals & insiders hold more shares of NYXH or PROF?

Summary

How does Nyxoah compare to Lucid Diagnostics?

Is NYXH or LUCD more profitable?

Does the media prefer NYXH or LUCD?

Do analysts prefer NYXH or LUCD?

Which has more volatility & risk, NYXH or LUCD?

Which has stronger valuation & earnings, NYXH or LUCD?

Do insiders & institutionals hold more shares of NYXH or LUCD?

Summary

How does Nyxoah compare to Sanara MedTech?

Does the media refer more to SMTI or NYXH?

Which has higher valuation and earnings, SMTI or NYXH?

Do institutionals and insiders hold more shares of SMTI or NYXH?

Is SMTI or NYXH more profitable?

Which has more risk and volatility, SMTI or NYXH?

Do analysts prefer SMTI or NYXH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NYXH vs. The Competition

Nyxoah Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools